KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Investing Activities (2018 - 2024)

Esperion Therapeutics (ESPR) has disclosed Cash from Investing Activities for 7 consecutive years, with -$167000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Cash from Investing Activities changed N/A year-over-year to -$167000.0, compared with a TTM value of -$167000.0 through Jun 2025, down 11.33%, and an annual FY2024 reading of -$317000.0, down 100.75% over the prior year.
  • Cash from Investing Activities was -$167000.0 for Q3 2024 at Esperion Therapeutics, down from -$77000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $33.0 million in Q3 2022 and bottomed at -$50.5 million in Q4 2021.
  • Average Cash from Investing Activities over 5 years is $1.5 million, with a median of $1.1 million recorded in 2020.
  • The sharpest move saw Cash from Investing Activities tumbled 341.98% in 2020, then surged 250.0% in 2023.
  • Year by year, Cash from Investing Activities stood at -$12.7 million in 2020, then tumbled by 298.26% to -$50.5 million in 2021, then skyrocketed by 76.64% to -$11.8 million in 2022, then surged by 248.38% to $17.5 million in 2023, then tumbled by 100.95% to -$167000.0 in 2024.
  • Business Quant data shows Cash from Investing Activities for ESPR at -$167000.0 in Q3 2024, -$77000.0 in Q2 2024, and -$73000.0 in Q1 2024.